Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Wagenlehner FM, et al. Among authors: yates k. Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16. Clin Infect Dis. 2016. PMID: 27313268 Free PMC article. Clinical Trial.
Reply to Johnson.
Wagenlehner FM, Newell P, Yates K, Gasink LB. Wagenlehner FM, et al. Among authors: yates k. Clin Infect Dis. 2017 Feb 1;64(3):391. doi: 10.1093/cid/ciw713. Epub 2016 Oct 24. Clin Infect Dis. 2017. PMID: 27941118 No abstract available.
Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M, Stone GG, Talley AK, Tawadrous M, Wajsbrot D, Yates K, Zuzova A, Gardner A. Bradley JS, et al. Among authors: yates k. Pediatr Infect Dis J. 2019 Aug;38(8):816-824. doi: 10.1097/INF.0000000000002392. Pediatr Infect Dis J. 2019. PMID: 31306396 Clinical Trial.
Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.
Bradley JS, Roilides E, Broadhurst H, Cheng K, Huang LM, MasCasullo V, Newell P, Stone GG, Tawadrous M, Wajsbrot D, Yates K, Gardner A. Bradley JS, et al. Among authors: yates k. Pediatr Infect Dis J. 2019 Sep;38(9):920-928. doi: 10.1097/INF.0000000000002395. Pediatr Infect Dis J. 2019. PMID: 31335570 Clinical Trial.
Renal impairment is prevalent in pediatric NAFLD/MASLD and associated with disease severity.
Mouzaki M, Yates KP, Arce-Clachar AC, Behling C, Blondet NM, Fishbein MH, Flores F, Adams KH, Hertel P, Jain AK, Molleston JP, Schwimmer JB, Vos MB, Xanthakos SA; NASH Clinical Research Network. Mouzaki M, et al. Among authors: yates kp. J Pediatr Gastroenterol Nutr. 2024 Jun 3. doi: 10.1002/jpn3.12272. Online ahead of print. J Pediatr Gastroenterol Nutr. 2024. PMID: 38828720
Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
Moore MP, Wang X, Kennelly JP, Shi H, Ishino Y, Kano K, Aoki J, Cherubini A, Ronzoni L, Guo X, Chalasani NP, Khalid S, Saleheen D, Mitsche MA, Rotter JI, Yates KP, Valenti L, Kono N, Tontonoz P, Tabas I. Moore MP, et al. Among authors: yates kp. Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933. Online ahead of print. Hepatology. 2024. PMID: 38776184
483 results